The Future 50

Courtesy of Regeneron Pharmaceuticals


Regeneron Pharmaceuticals


Investors are betting big on ­Regeneron: Its market value has jumped by more than a fifth in 2017. Why? Sales of eye-­disease treatment Eylea are strong. The company’s expansive pipeline could continue to fuel steady growth. Regeneron has 11 experimental treatments in Phase II or Phase III clinical trials. One that could prove critical is REGN2810, a type of next-generation medicine currently in late-stage studies that harnesses the body’s immune system to fight cancer.

Looking for leads, investment insights, or competitive intelligence?

Overall Score



Health Care




Leonard S. Schleifer



HQ Location

Tarrytown, N.Y.

Revenues ($M) (Past 12 Months)


Profits ($M) (Past 12 Months)


Market Value as of Oct. 9, 2017 ($M)


Revenue and net income for 12 months ended June 30, 2017. Source: S&P Global.

News about Regeneron Pharmaceuticals

The Diseases We Aren't Curing—And Why

Drug makers are flocking to certain treatment types. Why do others get left behind?

Read More →
Could a Vaccine Prevent High Cholesterol and Heart Disease?

Scientists are ready to move an experimental treatment into phase 1 trials.

Read More →
Trump's Proposed Science Cuts Could Devastate Future Generations, Pharma Expert Says

“We should only be working on two things, health and the freaking environment.”

Read More →
Pharma Executives Aren't Excited About Trump's Plans to Ease FDA Regulation

They say a robust review process is needed to convince doctors and insurers new drugs have value.

Read More →